XXX - Bifidobacterium animalis lactis CBT BL3 + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei CBT LC5 + Lactobacillus acidophilus CBT LA1 & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) encompasses a range of conditions, starting from the simple accumulation of fat in the liver to the more severe non-alcoholic steatohepatitis. There has been significant attention on the potential influence of the intestinal microbiome in the development of MASLD (1)

Study overview

This is a randomized, double-blind, placebo-controlled trial studying 2 capsules/day with Bifidobacterium animalis lactis CBT BL3 (32x10^9 CFU) + Inulin-type fructans (ITF) / Inulin (6.4 g) + Lacticaseibacillus casei CBT LC5 (16x10^9 CFU) + L…